Omnicell, Inc. — Q1 2019 Form 10-Q
Reporting period: Three months ended March 31, 2019; unaudited. Omnicell provides medication and supply dispensing automation, central pharmacy automation, analytics software, and medication-adherence solutions to healthcare customers. Effective January 1, 2019, the company began reporting as one operating segment following an organizational realignment.
Financial performance and liquidity
| Metric | Q1 2019 | Q1 2018 | Change |
|---|---|---|---|
| Total revenue | $202.5 million | $182.6 million | +11% |
| Product revenue | $145.6 million | $130.7 million | +11% |
| Services and other revenue | $56.9 million | $52.0 million | +10% |
| Gross profit / margin | $97.1 million / 48% | $82.5 million / 45% | Margin +3 points |
| Operating income / margin | $12.8 million / 6% | $0.6 million / less than 1% | Improved |
| Net income | $3.3 million | $2.7 million | +21% |
| Diluted EPS | $0.08 | $0.07 | +$0.01 |
| Cash from operations | $26.5 million | $18.9 million | +$7.6 million |
Product growth was driven primarily by a $12.8 million increase in automated dispensing cabinet revenue, particularly XT series products; services growth reflected higher renewal fees and a larger installed base. Management attributed gross-margin improvement to lower XT manufacturing ramp costs, economies of scale, and stabilized service costs. Operating expenses rose 3% to $84.4 million: lower R&D expense was more than offset by higher selling, general, and administrative expense.
Cash and cash equivalents were $77.2 million at March 31, 2019, versus $67.2 million at year-end. Working capital was $203.1 million and the current ratio was 2.0:1. Investing activities used $16.7 million, including $11.7 million for externally marketed software development and $5.0 million for property and equipment. Financing activities used $0.2 million: $39.0 million of debt repayment was largely offset by employee equity-plan proceeds and $20.2 million net proceeds from an at-the-market share offering.
Debt under the credit facilities was $101.0 million at quarter-end, down $39.0 million from year-end; the revolving facility had no borrowings. The company reported covenant compliance. Cash exceeded debt by approximately $23.8 million, before other obligations. The $315 million revolving credit facility remains available, subject to its terms.
Material changes and unusual items
- Income from operations increased substantially, but net income rose more modestly because the income-tax provision was $8.1 million, compared with a $4.8 million tax benefit in Q1 2018. Q1 2019 included a $9.6 million discrete tax expense related to an intellectual-property transfer, partly offset by a $4.6 million equity-compensation tax benefit. Q1 2018 included a $4.2 million discrete tax benefit from a check-the-box election.
- Omnicell adopted ASC 842 lease accounting on January 1, 2019. At March 31, it reported $63.9 million of operating lease right-of-use assets and $67.8 million of operating lease liabilities; adoption did not affect opening equity or prior-period results.
- The company sold approximately 243,000 shares through its ATM program for $20.6 million gross proceeds, at an average price of about $84.98 per share. $49.4 million remained available under the program. No shares were repurchased in the quarter.
- R&D expense declined partly because certain software projects reached the capitalization stage. Software development costs for external use were $11.7 million, versus $5.3 million in Q1 2018.
Outlook, risks, and contingencies
No specific numerical revenue or earnings guidance is provided in the supplied filing text. Management expects continued investment in differentiated products, new markets, acquisitions and partnerships, and its Autonomous Pharmacy strategy, including subscription and cloud-based offerings. It expects existing cash, operating cash flows, employee equity-plan proceeds, and available credit to meet needs for at least the next 12 months. Management cautions that quarterly results are not necessarily indicative of full-year results.
- Results depend on customer orders, capital budgets, installation timing and capacity, product acceptance, and the ability to supply products and consumables. Installation delays can defer revenue recognition.
- Key risks include competition and pricing pressure, healthcare-sector consolidation and spending constraints, product development and adoption, supplier concentration, international and currency exposure, cybersecurity and privacy obligations, and the execution of the Autonomous Pharmacy and subscription strategy.
- Legal proceedings include product-liability and negligence claims in Virginia and a class action alleging Illinois biometric-privacy violations. The company has recorded no accrual, stating potential loss is reasonably possible but not probable; the possible loss range cannot be reasonably estimated. A related insurer declaratory action was stayed.
- Non-cancelable purchase commitments totaled $71.0 million, of which $65.5 million was expected to be paid during 2019. Operating lease payments totaled $84.9 million over their stated maturities. Unrecognized tax benefits were $14.3 million; the timing and amount of any potential payment are uncertain.
- The company reported effective disclosure controls and no material change in internal control over financial reporting during the quarter.
Investor facts to verify
- Whether revenue growth and gross-margin gains persist, especially as XT manufacturing costs normalize and installations convert orders to revenue.
- The drivers and repeatability of the unusually high Q1 tax provision and the impact of discrete tax items on full-year earnings.
- Cash conversion and investment requirements, including capitalized software development, working-capital movements, and lease obligations.
- Debt repayment plans, covenant headroom, and potential dilution from the ATM program and employee equity awards.
- Developments and potential financial exposure in the disclosed litigation and uncertain tax positions.